Scott Han, OD
Optometrist · Sarasota, FLNPI 1104824051
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $91,798 of the $140,968 with a category attached, or 65.1%. 33 manufacturers reported payments, led by AbbVie at 47.9% of the total. Among optometrist clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 562 payments — averaging $250.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$68K
- Bausch & Lomb Americas Inc.$20K
- Sun Pharmaceutical Industries Inc.$18K
- Shire North American Group Inc$9K
- Nordic Pharma, Inc.$7K
- Biotissue Holdings Inc.$4K
- plus $15K from 27 others
Across 32 payments — averaging $345.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$10K
- Notal Vision, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$345
What the payments were for
- Consulting fees$17,04712%
- Speaking & faculty fees$91,79865%
- Travel & lodging$16,62912%
- Food & beverage$15,41911%
- Education$570%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 215 | $67,589 |
| Bausch & Lomb Americas Inc. | 90 | $20,413 |
| Sun Pharmaceutical Industries Inc. | 37 | $17,948 |
| Shire North American Group Inc | 19 | $9,043 |
| Nordic Pharma, Inc. | 1 | $7,000 |
| Biotissue Holdings Inc. | 43 | $3,902 |
| Eyevance Pharmaceuticals LLC | 7 | $3,758 |
| Apellis Pharmaceuticals, Inc. | 5 | $2,022 |
| Carl Zeiss Meditec USA, Inc. | 4 | $1,612 |
| Kala Pharmaceuticals, Inc. | 8 | $1,581 |
| Tarsus Pharmaceuticals, Inc. | 20 | $1,358 |
| Sight Sciences, Inc. | 15 | $815 |
| Alcon | 20 | $744 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $499 |
| Novartis | 12 | $437 |
| Aerie Pharmaceuticals, Inc. | 9 | $351 |
| Oyster Point Pharma, Inc. | 7 | $330 |
| Dompe US, Inc. | 5 | $305 |
| Amgen(2 entities) | 5 | $297 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $227 |
| Notal Vision, Inc. | 4 | $132 |
| Optovue, Inc. | 1 | $93 |
| Ocular Therapeutix, Inc. | 3 | $91 |
| Regeneron Healthcare Solutions, Inc. | 3 | $88 |
| Johnson & Johnson Vision Care, Inc. | 3 | $73 |
| Harrow Eye, LLC | 4 | $67 |
| Alimera Sciences, Inc. | 3 | $65 |
| Carl Zeiss Meditec, Inc. | 1 | $31 |
| Boehringer Ingelheim | 1 | $26 |
| Genentech USA, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Alcon Research LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VUITY$31,553
- XIIDRA$27,297
- LUMIGAN$20,273
- MIEBO$18,506
- CEQUA$17,449
- RESTASIS MULTIDOSE$7,866
- Lacrifill$7,000
- COMBIGAN$6,900
- DURYSTA$2,383
- ALPHAGAN P$1,550
- CIRRUS HD-OCT$1,530
- CLARUS$1,530
- FORUM$1,530
- Humphrey Field Analyzer (HFA3)$1,530
- IOLMaster 700$1,530
- Tobradex ST$1,500
- EYSUVIS$1,490
- Flarex$1,149
- XEN GLAUCOMA TREATMENT SYSTEM$1,125
- Syfovre$1,089
How this compares
$140,968 in reported general payments places this provider in the 95th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 748 | $285,057 |
| RestasisCyclosporine | 233 | $276,676 |
| MieboPerfluorohexyloctane/Pf | 237 | $183,728 |
| CequaCyclosporine | 158 | $116,284 |
| XiidraLifitegrast | 128 | $111,904 |
| XdemvyLotilaner | 35 | $65,482 |
| TyrvayaVarenicline Tartrate | 88 | $61,894 |
| CombiganBrimonidine Tartrate/Timolol | 158 | $44,449 |
| EysuvisLoteprednol Etabonate | 75 | $37,225 |
| Alphagan PBrimonidine Tartrate | 88 | $24,811 |
| VyzultaLatanoprostene Bunod | 59 | $24,247 |
| Cyclosporine | 44 | $21,952 |
| RocklatanNetarsudil Mesylat/Latanoprost | 45 | $17,530 |
| VevyeCyclosporine | 18 | $14,780 |
| Lotemax SmLoteprednol Etabonate | 35 | $9,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $67,589 | $630,9931,227 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $20,413 | $319,880424 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $17,948 | $116,284158 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,358 | $65,48235 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $330 | $61,89488 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $1,581 | $37,22575 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Besivance, Loteprednol Etabonate | $499 | $19,82679 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $351 | $17,53045 claims |
| Harrow Eye, LLCVevye | $67 | $14,78018 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $3,758 | $4,98922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,166 optometrist providers in Florida.
Other optometrist in Sarasota
- Donna ShotwellSarasota$35K
- James HoffmanOrange Park$795K
- April JasperWest Palm Beach$553K
- Nora CothranLargo$505K
- Michael SluskyNorth Port$384K
- Katie SpearDefuniak Springs$361K
- Karen HoffmanOrange Park$282K
- Ashley RothMiami Beach$261K
- Jessica SteenDavie$256K
- Mark DunbarMiami$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.